LYRA Projected Dividend Yield
Lyra Therapeutics Inc ( NASDAQ : LYRA )Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Co. has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. 21 YEAR PERFORMANCE RESULTS |
LYRA Dividend History Detail LYRA Dividend News LYRA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |